Skip to Main Content

Paper Details

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models.
npj Breast Cancer
5
2021
BC, BCM-3963 model, BCM-3963 patient-derived BC xenografts, BT474-, BT474-AZ, ER, HER, HER2, HER2+, HER2+ BT474-AZ (ER+) cell, HER2-positive breast cancer, HER2-positive breast cancer xenograft models, Ki67, Lapatinib, Neratinib, Phosphorylated HER receptor, breast cancer, estrogen, estrogen receptor, estrogen receptor (ER)+ tumors, mice, neratinib, pERK, pS6, patient, pertuzumab, phosphorylated (p) AKT, trastuzumab, tumor, tumors
Author NameAffiliation
Susan G HilsenbeckBaylor College of Medicine
Susan G HilsenbeckDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
Mothaffar F RimawiBaylor College of Medicine
Mothaffar F RimawiDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
Mothaffar F RimawiBaylor College of Medicine
Charles Kent OsborneBaylor College of Medicine
Charles Kent OsborneDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
Charles Kent OsborneBaylor College of Medicine
Charles Kent OsborneBaylor College of Medicine
  • 1 - 9

Datasets

Release 1.2